Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. September 2024 09:00 ET | Quelle: Bright Mountain Media, Inc.

Bright Mountain Media Appoints Elaine Riddell as Non-Executive Director Bringing 15 Years of Experience Driving Transformative Growth

Boca Raton, FL, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bright Mountain Media, Inc. (OTCQB: BMTM) ("Bright Mountain" or the "Company"), a global marketing services platform with current investments in...
13. November 2023 09:00 ET | Quelle: Harvard Apparatus Regenerative Technology, Inc.

Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results

Holliston, MA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) (“Harvard Apparatus Regenerative Technology” or the “Company”), a clinical-stage...
21. September 2023 16:00 ET | Quelle: Spherix Global Insights

Spherix Global Insights Announces New Leadership to Drive Growth and Innovation

Exton, Pennsylvania, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Spherix Global Insights, a leading provider of market data and insights to the pharmaceutical industry, is thrilled to announce the appointment...
21. Juni 2023 07:30 ET | Quelle: Blue Water Biotech, Inc.

Blue Water Biotech Collaborates with IQVIA to Build Medical Sales Representative Team to Market Commercial Product Portfolio

CINCINNATI, June 21, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”) (Nasdaq: BWV), a biotechnology and pharmaceutical company spanning multiple sectors, today...
23. Juni 2020 07:00 ET | Quelle: Mateon Therapeutics, Inc.

Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients

AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
13. November 2017 10:52 ET | Quelle: WellDoc Inc.

IQVIA Institute Rates WellDoc’s BlueStar® as “Top App” in Clinical Diabetes Treatment

COLUMBIA, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) -- WellDoc®, a leading digital health company, announced today that IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar®,...